Is joint preservation still an option for my ankle or hip?

Hearing that a hip or ankle is “too young for replacement” often happens after an MRI report shows a specific cartilage injury rather than end‑stage “bone‑on‑bone” arthritis. The immediate question is whether the joint can be preserved for long enough to stay active, or whether the damage has already moved into the replacement pathway.

In day‑to‑day practice, options tend to sit on a simple ladder: symptom management (physiotherapy, activity changes, footwear/orthotics, and simple injections), biologic or injection support used as adjuncts in selected cases, cartilage restoration or scaffold repair (for a defined damaged patch), and finally joint replacement when degeneration is widespread and progressive.

Focal cartilage defects are the situations where repair is most often considered: one main “pothole” in the surface, with otherwise reasonable joint space. For osteochondral lesions of the talus, treatment discussions commonly distinguish between smaller, contained defects (where non‑operative care and/or marrow‑stimulation procedures may be considered) versus larger, deeper, cystic, or mechanically unstable defects (where more structural reconstruction can be discussed). This contrasts with diffuse arthritis, where focal repair usually becomes less realistic.

Clinic letters may refer to Outerbridge or ICRS grading (how deep the damage is) and defect size (often in cm²). Outcomes still depend on factors such as age, activity level, lesion location and existing arthritis—aiming to reduce pain and improve function rather than “make the joint new”.

At MSK Doctors—CQC‑rated “Good” and consultant‑led in Sleaford (NG34) and Grantham (NG31)—assessment sometimes combines detailed imaging review (including onMRI™ support) with objective movement testing (MAI Motion®) to clarify whether symptoms fit a focal repair problem or more general joint wear.

Ankle talar dome lesions: which treatments are realistic for me?

A talar dome lesion is usually described in clinic as a “pothole” in the smooth joint surface on the top of the talus (the ankle bone), often involving both the cartilage and the bone underneath. These defects are a common reason for ongoing ankle pain after an injury such as a sprain, particularly when symptoms persist despite time and rehabilitation (for example, pain on stairs or a sense of “catching”).

Early management is typically about settling symptoms and controlling load rather than “filling the pothole”: activity modification, physiotherapy to restore ankle movement and strength, and bracing or footwear changes are commonly used. Smaller lesions are often managed non‑operatively first, with surgery considered when symptoms remain limiting or mechanical symptoms persist.

Once surgery is on the table, surgeons often explain the pathway in a simple “small and contained” versus “bigger or deeper” way (rather than leading with acronyms). Marrow‑stimulation procedures (microfracture/drilling/abrasion) are commonly discussed for smaller lesions, while larger defects—or cases that have failed conservative care or prior procedures—are more likely to prompt discussion about structural grafting (osteochondral autograft or allograft) to better restore joint contour and mechanical strength; cell‑based or matrix‑assisted options are also used in selected settings.

Two practical contrasts capture why size and “where the defect sits” can change the plan. Finite‑element modelling of talar osteochondral defects (about 4.5–9 mm diameter) found that lesions in the posteromedial (zone 7), anterolateral (zone 3), and mid‑posterior (zone 8) regions produced the greatest reductions in ankle stiffness as defects enlarged, while posterolateral zone 9 was least critical—supporting a rationale for more robust restoration/augmentation in more mechanically sensitive zones in some cases. [1]

When does OATS or mosaicplasty make sense for the ankle?

OATS (often called mosaicplasty) is usually chosen when the main problem is not just damaged cartilage, but a missing “plug” of cartilage and the supporting bone beneath it. In a single operation, small cylinders of cartilage‑on‑bone are taken from a lower‑load area of the knee and press‑fitted into the talar defect, aiming to restore the joint surface contour and the defect’s mechanical strength rather than relying on a softer “scar‑cartilage” repair tissue. [2]

In practical decision-making, it helps to frame OATS as the ‘structural’ option—most commonly discussed for larger, symptomatic talar dome lesions, particularly when conservative care or a previous procedure has not settled symptoms, or when MRI suggests deeper subchondral bone involvement/cystic change. Modelling work suggests that some higher‑load talar locations (zones 7, 3, and 8) lose stiffness more as defects enlarge—situations where a more robust reconstruction may be favoured. [1]

Published outcomes are one reason it stays on the table. In a 156‑patient comparative surgical series that included OATS, antegrade drilling/microfracture and other techniques, OATS had the highest satisfaction (about 90%), and each intervention was associated with significantly decreased pain and increased function post‑operatively. [3] A separate >10‑year follow‑up series (19 patients) reported complete graft incorporation with 89% “satisfied or neutral”, alongside preservation of osteoarthritis grade in about 53%—suggesting durability for many, while also acknowledging that arthritis progression is not always prevented. [4]

The trade-offs are also structural: an operation under anaesthetic, and—especially for medial talar lesions—sometimes a medial malleolar osteotomy for access. In an 11‑patient technical series using a triplanar osteotomy, full weight‑bearing was reported at a mean of about 5 weeks with no non‑union or fragment shift, suggesting osteotomy morbidity can be reduced with technique (though it is still an added step). [5] The other key compromise is the knee donor site, where discomfort or damage at the harvest area is a recognised concern. OATS is therefore less compelling when the lesion is small and contained, or where ankle arthritis is already diffuse rather than focal.

Could an injectable scaffold such as ChondroFiller help my ankle?

Injectable collagen scaffolds sit in a different space from plug‑transfer surgery: rather than replacing the damaged area with cartilage‑and‑bone, they aim to fill a focal defect with a collagen “gel” or matrix that acts like a temporary sponge. The idea is to provide a structure that helps the body’s own repair cells populate the defect over time (often described as matrix‑induced chondrogenesis), without taking osteochondral plugs from the knee. ChondroFiller is one example of a cell‑free collagen type I hydrogel used clinically as a defect “filler”. [6,7]

A more established scaffold approach in the ankle is matrix‑augmented bone‑marrow stimulation (M‑BMS), where a collagen scaffold is combined with a marrow‑stimulation procedure. In the German Cartilage Register (45 patients with medial talar lesions), M‑BMS plus a type I/III collagen scaffold was associated with significant improvements at 12 months in FAAM‑ADL and multiple FAOS domains (including pain and quality of life), with similar outcomes whether or not a medial malleolar osteotomy was needed for access. [8]

For ChondroFiller specifically in the talus, the published ankle literature remains limited: it has been described as feasible in small clinical reports with short‑term outcomes, but without randomised head‑to‑head comparisons against established options such as microfracture or OATS. [6,7]

In practical terms, that uncertainty translates into a trade‑off: patients prioritising the most established durability data for larger or deeper talar defects will generally not find it in ChondroFiller ankle studies yet, whereas patients prioritising a less invasive pathway (and avoiding knee graft harvest) may consider an injectable scaffold if the lesion pattern is suitable and they accept shorter follow‑up evidence. In MSK Doctors’ current pathway, ChondroFiller is delivered as an ultrasound‑guided outpatient injectable scaffold treatment (image‑guided placement rather than arthroscopy), typically alongside a detailed MRI review.

Early signals from other joints help frame what is known—and what is not. A 2025 hip arthroscopy case report (32‑year‑old; 15×5 mm femoral head defect) described complete pain relief and full range of motion after ChondroFiller alone at short‑term follow‑up. [6] In a separate 2025 prospective distal radius fracture study (n=59; 25 ChondroFiller‑treated defects), follow‑up arthroscopy showed better cartilage appearance scores (Outerbridge and ICRS) than controls, but fibrous tissue was reported when defects were overfilled, and long‑term clinical benefit remained unclear. [7]

Hip cartilage repair with OCA: when is it worth trying?

Hip osteochondral allograft (OCA) is a joint-preserving operation where a size-matched piece of donor cartilage with its underlying bone is shaped and transplanted into a damaged segment of the femoral head (the “ball” of the hip). The intent is to restore a more normal joint surface and supporting bone in a focal area, rather than replacing the whole joint with a prosthesis. [9]

In practice, OCA is usually discussed for a narrow group: younger, high-demand patients with a sizeable localised defect and relatively preserved joint space, not for general “wear-and-tear” arthritis across the whole hip. In a 29-patient series (mean age 21.6 years), typical underlying causes included developmental dysplasia and post-traumatic defects (both 31%), femoroacetabular impingement (17%), Perthes sequelae (10%), and avascular necrosis (AVN) (7%). [10]

The most useful way to judge whether it is “worth trying” is to look at what success and failure tend to mean in published cohorts at around 3–4 years. In a 24-patient study (mean age 22.4; mean lesion size 488 mm²), hip function scores improved (mHHS 62.1 to 83.9; iHOT-12 35.5 to 77.5), but 6 of 24 patients (25%) still converted to hip arthroplasty at a mean of 3.8 years. [9]

A second series (29 patients; mean lesion size 418 mm²) reported similar improvements (mHHS 58.5 to 84.1; iHOT-12 34.7 to 77.9) with 4 of 29 (13.7%) converting to arthroplasty at roughly 41.5 months. [10]

AVN sits in a particularly selective niche: reports in symptomatic Ficat stage II–III AVN describe pain/function improvement with imaging evidence of graft incorporation at early follow-up, but long-term hip preservation is still uncertain—and once there is established collapse or widespread arthritis, the logic for OCA becomes weaker. [11]

Technique and graft handling may matter. In a 33-patient hip-preservation series using femoral head OCA and/or labral allograft, overall success was 84.8%, and outcomes were strongly associated with preservation method (50% success with standard-preserved grafts versus 100% with MOPS at ≥1 year). [12]

There are no randomised trials comparing femoral head OCA with modern total hip replacement, so selection depends on careful clinical assessment and shared decision-making, balancing the goal of delaying arthroplasty against the possibility of later conversion.

How the MSK Doctors team helps you choose the right path

Choosing between cartilage-preserving options in the ankle and hip rarely comes down to a single “best” procedure; in this final step, the emphasis stays on the decision questions that shape a sensible plan, with service details kept brief. The strongest published signals still point in different directions depending on joint and defect—such as >10‑year durability reported after talar mosaicplasty in a 19‑patient series, versus mid‑term hip OCA series where 13–25% converted to arthroplasty by around 3–4 years. [4,9,10]

Key questions that usually determine the “right path” include:

• Defect burden: size and location (finite‑element modelling suggests zones 7/3/8 may be more mechanically sensitive than zone 9), and whether the subchondral bone is part of the problem. [1]
• Joint context: how much background arthritis exists elsewhere in the joint, and what “success” means (symptom relief, sport, or delaying replacement).
• Track record versus invasiveness: in the ankle, published comparative data include a 156‑patient series in which OATS had the highest satisfaction (about 90%) across multiple techniques; a separate 19‑patient series suggests durable outcomes beyond 10 years in selected larger lesions. Collagen matrix approaches also have encouraging 12‑month registry outcomes in selected medial lesions; injectable scaffolds (including ChondroFiller) remain earlier in the evidence cycle, with limited short‑term reports and without randomised comparisons to established options. [3,4,8,6,7]

Across MSK Doctors (Sleaford, NG34 and Grantham, NG31), decisions are led by consultant assessment, with MRI review and—where helpful—objective biomechanics (MAI Motion®) to clarify loading drivers that can make or break cartilage procedures; London-based care is available via the London Cartilage Clinic when needed. For a personalised review, appointments can be booked online without GP referral at mskdoctors.com.

1. [1] Outcomes associated with hip preservation using osteochondral allograft transplants and acetabular labrum reconstruction. (2024). https://doi.org/10.1177/11207000241288445 https://doi.org/10.1177/11207000241288445